Adamas Pharma rises after IPO raises $48 million

Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

In morning trading, the stock added $1, or 6.3 percent, to $17.

Adamas Pharmaceuticals Inc. is developing drugs that treat central nervous system disorders such as Parkinson's and Alzheimer's disease. It worked with Forest Laboratories Inc. on Namenda XR, an extended-release version of a Forest drug that treats Alzheimer's. The two companies have been studying a that combines Namenda XR with donepezil, or Aricept. Forest filed for approval of that pill in March.

Shares of the Emeryville, Calif., company are trading under the symbol "ADMS" on the Nasdaq Global Market.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Veeva Systems stock soars on debut

Oct 16, 2013

Shares of Veeva Systems Inc. are soaring in their trading debut Wednesday after the cloud-based software company raised about $261 million in its initial public offering.

Recommended for you

A new tool in drug overdose prevention

6 hours ago

The Center for Disease Control reported earlier this month that the heroin overdose death rate across 28 states it surveyed doubled between 2010 and 2012. This sharp increase and the chilling statistics that say more than 11 ...

Nasal spray treats heroin overdose

Oct 28, 2014

"Every year, drug overdoses are responsible for roughly 1000 ambulance calls in Oslo," says Arne Skulberg, an anaesthesiologist, a PhD candidate at NTNU and the 2014 winner of Norway's Researcher Grand Prix ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.